Summary of diagnostic yield of familial pancreatic cancer screening and surveillance programmes
| Study | High-risk group | Imaging tests | Diagnostic yield*n (%) |
|---|---|---|---|
| Brentnall 1999 (1) n=14 | FPC | EUS+ERCP+CT | 7/14 (50)† |
| Kimmey 2002 n=46‡ | FPC | EUS; ERCP§ | 12/46 (26)† |
| Canto 2004 (2) n=38 | FPC, PJS | EUS; ERCP§, EUS-FNA§, CT§ | 2/38 (5.3)† |
| Canto 2006 (3) n=78 | FPC, PJS | EUS; CT§,EUS-FNA§, ERCP§ | 8/78 (10.3)¶,† |
| Poley 2009 (4) n=44 | FPC, BRCA, PJS, p16, p53, HP | EUS;CT§, MRI§ | 10/44 (23) |
| Langer 2009 (5) n=76 | FPC, BRCA | EUS+MRCP; EUS-FNA§ | 1/76 (1.3)¶,† |
| Verna 2010 (6) n=51 | FPC, BRCA, p16 | EUS and/or MRCP | 6/51 (12)† |
| Ludwig 2011 n=109 | FPC, BRCA | MRCP; EUS§, EUS-FNA§ | 9/109 (8.3)¶ |
| Vasen 2011 (7) n=79 | p16 | MRI/MRCP | 14/79† (18) |
| Al-Sukhni 2011 (8) n=262 | FPC, BRCA, PJS, p16, HP | MRI; CT§, EUS§, ERCP§ | 19/262¶ (7.3) |
| Schneider 2011 (9)** n=72 | FPC, BRCA, PALB2 | EUS+MRCP | 11/72 (15)¶ |
| Canto 2012 (10) n=216 | FPC, BRCA, PJS | CT, MRI/MRCP, EUS; ERCP§ | 5/216 (2.3)†–92/216 (43) |
*Yield is defined as the detection of any pathologically proven (pre)malignant lesion (≥PanIN-2/IPMN and pancreatic adenocarcinoma) and lesions that are morphologically suspicious for branch-duct IPMNs.
†Includes only pathologically proven pancreatic neoplasms (histology or cytology).
‡Continuation of Brentnall 1999, included 14 high-risk individuals from Brentnall 1999.
§Test performed only as an additional test for detected abnormalities.
¶Includes baseline and follow-up.
**Continuation of Langer 2009, includes high-risk individuals from this series.
ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasonography; FNA, fine-needle aspiration; FPC, familial pancreatic cancer; IPMN, intraductal papillary mucinous neoplasm; MRCP, magnetic resonance cholangiopancreatography; PJS, Peutz–Jeghers syndrome; PanIN, pancreatic intraepithelial neoplasia.